Microbiome Therapeutic Market

Table of Content

1. Executive Summary

    1.1. Market Overview

    1.2. Market Analysis

    1.3. PMR Analysis and Recommendations

2. Market Introduction

    2.1. Market Definition

    2.2. Market Taxonomy

    2.3. Microbiome Therapeutics Market Overview

3. Market View Point

    3.1. Market Dynamics

        3.1.1. Macro-Economic Factors

        3.1.2. Drivers

        3.1.3. Restraints

        3.1.4. Trends

4. Venture Capital Financing

5. Pipeline Analysis

6. Global Microbiome Therapeutics Market Opportunity Assessment 2018-2025

    6.1. Market Opportunity Assessment (US$ Mn) and Analysis By Indication

        6.1.1. Type 2 Diabetes

            6.1.1.1. U.S.

            6.1.1.2. Europe

            6.1.1.3. Japan

            6.1.1.4. RoW

        6.1.2. C. difficile infection

            6.1.2.1. C. difficile Infection

                6.1.2.1.1. U.S.

                6.1.2.1.2. Europe

                6.1.2.1.3. Japan

                6.1.2.1.4. RoW

            6.1.2.2. Recurrent C. difficile Infection

                6.1.2.2.1. U.S.

                6.1.2.2.2. Europe

                6.1.2.2.3. Japan

                6.1.2.2.4. RoW

        6.1.3. Obesity

        6.1.4. Primary Hyperoxyurea

7. Global Microbiome Therapeutics Market Potential

    7.1. Microbiome Therapeutics Market Potential for C. difficile Infection Treatment

    7.2. Microbiome Therapeutics Market Potential for Preterm Birth and Gynecology Conditions

    7.3. Microbiome Therapeutics Market Potential for Diabetes

    7.4. Microbiome Therapeutics Market Potential for Obesity

8. Competition Landscape

    8.1. Company Profiles (Details - Overview, pipeline, Strategy, Recent Developments)

        8.1.1. Microbiome Therapeutics Inc.

        8.1.2. SERES Therapeutics Inc.

        8.1.3. LNC Therapeutics Inc.

        8.1.4. Vedanta Biosciences Inc.

        8.1.5. Enterome SA

        8.1.6. Ferring B.V.

        8.1.7. ViThera Pharmaceuticals Inc.

        8.1.8. Second Genome Therapeutics

        8.1.9. Rebiotix

        8.1.10. Synlogic Inc.

        8.1.11. 4D Pharma Plc.

        8.1.12. Ritter Pharmaceuticals

        8.1.13. AvidBiotics

        8.1.14. Osel Inc.

        8.1.15. OxThera AB

        8.1.16. Evelo Biosciences

        8.1.17. AOBiome LLC

        8.1.18. Immuron Ltd.

9. Assumptions and Acronyms Used

10. Research Methodology

Report Sample is Available

In-depth report coverage is now just a few seconds away

Get FREE Report Sample

List Of Table

Table 01: Activities in Microbiome Research Across the Globe (1/2)

Table 02: Activities in Microbiome Research Across the Globe (2/2)

Table 03: Global Microbiome Therapeutics Market Partnership and Collaborations (1/6)

Table 04: Global Microbiome Therapeutics Market Partnership and Collaborations (2/6)

Table 05: Global Microbiome Therapeutics Market Partnership and Collaborations (3/6)

Table 06: Global Microbiome Therapeutics Market Partnership and Collaborations (4/6)

Table 07: Global Microbiome Therapeutics Market Partnership and Collaborations (5/6)

Table 08: Global Microbiome Therapeutics Market Partnership and Collaborations (6/6)

Table 09: Venture Capital Investments in Microbiome Therapeutics (2017)

Table 10: Venture Capital Investments in Microbiome Therapeutics (2016) (1/3)

Table 11: Venture Capital Investments in Microbiome Therapeutics (2016) (2/3)

Table 12: Venture Capital Investments in Microbiome Therapeutics (2016) (3/3)

Table 13: Venture Capital Investments in Microbiome Therapeutics (2015) (2/3)

Table 14: Venture Capital Investments in Microbiome Therapeutics (2014)

Table 15: Venture Capital Investments in Microbiome Therapeutics (2013)

Table 16: Venture Capital Investments in Microbiome Therapeutics (2011-2012)

Table 17: Microbiome Therapeutics Pipeline Analysis (1/11)

Table 18: Microbiome Therapeutics Pipeline Analysis (2/11)

Table 19: Microbiome Therapeutics Pipeline Analysis (3/11)

Table 20: Microbiome Therapeutics Pipeline Analysis (4/11)

Table 21: Microbiome Therapeutics Pipeline Analysis (5/11)

Table 22: Microbiome Therapeutics Pipeline Analysis (6/11)

Table 23: Microbiome Therapeutics Pipeline Analysis (7/11)

Table 24: Microbiome Therapeutics Pipeline Analysis (8/11)

Table 25: Microbiome Therapeutics Pipeline Analysis (9/11)

Table 26: Microbiome Therapeutics Pipeline Analysis (10/11)

Table 27: Microbiome Therapeutics Pipeline Analysis (11/11)

Table 28: Global Microbiome Therapeutics Market Opportunity Assessment, By Type 2 Diabetes Indication, 2018-2025

Table 29: Global Microbiome Therapeutics Market Opportunity Assessment, C. difficile Infection, 2018-2025

Table 30: Global Microbiome Therapeutics Market Opportunity Assessment, By ObesityIndication, 2018-2025

Table 31: Global Microbiome Therapeutics Market Opportunity Assessment, By Obesity Indication, 2018-2025

Table 32: Research Programs in the Field Microbiome in Preterm/Premature Birth (1/2)

Table 33: Research Programs in the Field of Microbiome in Preterm/Premature Birth (2/2)

Table 34: Seres Therapeutics Inc. Microbiome Therapeutics Pipeline Analysis

Table 35: Vedanta Biosciences Inc. Microbiome Therapeutics Pipeline Analysis

Table 36: Second Genome Therapeutics Microbiome Therapeutics Pipeline Analysis

Table 37: Rebiotix, Inc. Microbiome Therapeutics Pipeline Analysis

Table 38: Synlogic, Inc. Microbiome Therapeutics Pipeline Analysis

Table 39: 4D Pharma PLC. Microbiome Therapeutics Pipeline Analysis

Table 40: OxThera AB. Microbiome Therapeutics Pipeline Analysis

Table 41: Immuron Ltd IMC. Microbiome Therapeutics Pipeline Analysis

Table 42: Enterome Bioscience SA. Microbiome Therapeutics Pipeline Analysis

Table 43: Evelo Biosciences Inc., Microbiome Therapeutics Pipeline Analysis

Table 44: MicroBiome Therapeutics LLC., Microbiome Therapeutics Pipeline Analysis

Table 45: LNC Therapeutics, SA. Microbiome Therapeutics Pipeline Analysis

Table 46: Microbiome Therapeutics, LLC Pipeline Analysis

Table 47: Microbiome Therapeutics, LLC Pipeline Analysis

Table 48: Microbiome Therapeutics, LLC Pipeline Analysis

Table 49: Osel Inc. Microbiome Therapeutics Pipeline Analysis

Table 50: Ritter Pharmaceuticals Inc. Microbiome Therapeutics Pipeline Analysis

Table 51: AOBiome Microbiome Therapeutics Pipeline Analysis

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

Get a Customized Version

- List Of Chart -

Figure 01: Global Microbiome Therapeutics Market Opportunity By Indication (2025)

Figure 02: Number of Partnerships and Collaboration Deals in Microbiome Therapeutics Market (2010 - 2017)

Figure 03: Partnerships and Collaborations Among Microbiome Industry

Figure 04: Trends in Venture Capital Investments in Microbiome Therapeutics (2011 - 2017)

Figure 05: Distribution of Industry sponsored Pipeline Projects for Microbiome Therapeutics, by Indication

Figure 06: Distribution of Industry sponsored Pipeline Projects for Microbiome Therapeutics, By Phase

Figure 07: Geographical Distribution of Clinical Trials for Microbiome

Figure 08: Distribution of Microbiome Clinical Trials, By Drug Type

Figure 09: Number Microbiome Therapeutics Drug Pipeline Projects By Indication (September 2017)

Figure 10: Global Microbiome Therapeutics Market Value (US$ Mn) Opportunity Assessment 2018-2025

Figure 11: Global Type 2 Diabetes Microbiome Therapeutics Market Opportunity Assessment (2018-2025)

Figure 12: Global Type 2 Diabetes Microbiome Therapeutics Market Opportunity by Region (2025)

Figure 13: Global C. difficile Infection Microbiome Therapeutics Market Opportunity Assessment (2018-2025)

Figure 14: Global C. difficile Infection Microbiome Therapeutics Market Opportunity by Region (2025)

Figure 15: Global Obesity Microbiome Therapeutics Market Opportunity Assessment (2018-2025)

Figure 16: Global Obesity Microbiome Therapeutics Market Opportunity by Region (2025)

Figure 17: Global Primary Hyperoxyurea Microbiome Therapeutics Market Opportunity Assessment (2018-2025)

Figure 18: Global Primary Hyperoxyurea Microbiome Therapeutics Market Opportunity by Region (2025)

Figure 19: Global CDI Treatment Market (US$ Mn ) 2025 (F) and Microbiome Therapeutics Opportunity

Figure 20: Incidence of C. difficile Infection Across Major Countries as Percentage of Total Hospital Admissions (2016)

Figure 21: Composition of Microbiome of Reproductive Organs

Figure 22: Number of People(Mn) with Diabetes, By Region (2015 & 2040)

Figure 23: Global Diabetes Treatment Market (US$ Mn ) 2025 (F) and Microbiome Therapeutics Opportunity

Figure 24: Top Ten Countries/Territories For Diabetes Related Health Expenditure (2015)

Figure 25: Global Obesity Treatment Market (US$ Mn ) 2025 (F) and Microbiome Therapeutics Opportunity

Figure 26: Number of people (Mn) with Obesity (2016 & 2020)

Figure 27: Seres Therapeutics Inc. Microbiome Activity Analysis

Figure 28: Vedanta Biosciences Microbiome Activity Analysis

Figure 29: Second Genome Inc. Microbiome Activity Analysis

Figure 30: Second Genome Therapeutics Pipeline Active and Inactive Programs By Indication

Figure 31: Rebiotix Inc. Microbiome Activity Analysis

Figure 32: Synlogic Inc. Microbiome Activity Analysis

Figure 33: 4D pharma PLC. Microbiome Activity Analysis

Figure 34: OxThera AB Microbiome Activity Analysis

Figure 35: OxThera AB Pipeline Programs By Phase

Figure 36: Immuron Ltd. Microbiome Activity Analysis

Figure 37: Enterome Biosciences SA Microbiome Activity Analysis

Figure 38: Evelo Biosciences Inc. Microbiome Activity Analysis

Figure 39: Evelo Biosciences Inc. Pipeline Active and Inactive Programs By Indication

Figure 40: Microbiome Therapeutics Inc. Activity Analysis

Figure 41: Microbiome Therapeutics Inc. Pipeline, Active and Inactive Programs By Indication

Figure 42: Ferring B.V. Microbiome Activity Analysis

Figure 43: ViThera Pharmaceuticals, Inc. Microbiome Activity Analysis

Figure 44: C3J Therapeutics, Inc. Microbiome Activity Analysis

Figure 45: C3J Therapeutics Inc. Pipeline Active and Inactive Programs By Indication

Figure 46: Second Genome Inc. Microbiome Activity Analysis

Figure 47: Osel Pipeline Active and Inactive Programs By Indication

Figure 48: Second Genome Inc. Microbiome Activity Analysis

Figure 49: Second Genome Inc. Microbiome Activity Analysis

Figure 50: AOBiome Clinical Pipeline Programs By Indication